Loading clinical trials...

UNKNOWN

Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease

NCT05151458•Assiut University

Summary

Ulcerative colitis (UC) and Crohns disease (CD) represent the two major forms of inflammatory bowel disease (IBD), characterized by epithelial cell damage and prominent mucosal infiltration by inflammatory cells including granulocytes, macrophages, lymphocytes, and plasma cells.

Eligibility

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Male and female gender. Disease activity proven clinically and endoscopy . Assiut university hospital patients

Exclusion Criteria

•Patients who refuse to contribute in this study Pregnancy and breast feeding Cancer patients Renal pathology Diabetes Mellitus Cardiovascular patients Pancreatitis COPD patients

Key Dates

Start Date

December 29, 2021

Primary Completion Date

November 29, 2022

Completion Date

November 30, 2022

Last Updated

December 14, 2021

Enrollment

ESTIMATED participants

Conditions

Inflammatory Bowel Diseases

Contacts

Mohamed Alsadek Ma Ghozaly, Master

CONTACT

01150993206 alsadekmohamed215@gmail.com

Hossam Ma Abd Alwahab

CONTACT

01146539976

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITING

Institutional Registry of Rare Diseases

NCT06573723

Rare DiseasesAmyloidosis+24 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 14, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Institutional Registry of Rare Diseases

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study

Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance

Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)

Therapeutic Endpoint in Pediatric IBD Conditions